Brexit Talks Must Prioritize Patient Access, Avoid Regulatory Divergence, Says EFPIA
Executive Summary
Patient access to new drugs must be a priority in the negotiations over the UK's exit from the EU, as must the need to ensure that the UK and EU drug regulatory systems don't diverge, says the European industry federation, EFPIA, one week after the momentous vote.